$0.34
6.58% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US81728A1088
Symbol
SNSE
Sector
Industry

Sensei Biotherapeutics Inc Stock price

$0.37
-0.07 15.08% 1M
-0.14 28.24% 6M
-0.12 25.32% YTD
-0.62 63.03% 1Y
-1.87 83.66% 3Y
-18.63 98.07% 5Y
-18.63 98.07% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.02 6.09%
ISIN
US81728A1088
Symbol
SNSE
Sector
Industry

Key metrics

Market capitalization $9.23m
Enterprise Value $-28.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.14
P/B ratio (TTM) P/B ratio 0.24
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-31.66m
Free Cash Flow (TTM) Free Cash Flow $-24.82m
Cash position $41.34m
EPS (TTM) EPS $-1.20
P/E forward negative
Short interest 0.72%
Show more

Is Sensei Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Sensei Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Sensei Biotherapeutics Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Sensei Biotherapeutics Inc forecast:

Buy
100%

Financial data from Sensei Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.55 0.55
65% 65%
-
-0.55 -0.55
65% 65%
-
- Selling and Administrative Expenses 12 12
26% 26%
-
- Research and Development Expense 19 19
5% 5%
-
-31 -31
12% 12%
-
- Depreciation and Amortization 0.55 0.55
65% 65%
-
EBIT (Operating Income) EBIT -32 -32
14% 14%
-
Net Profit -30 -30
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sensei Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sensei Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
one day ago
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity...
Neutral
GlobeNewsWire
6 days ago
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population -
Neutral
GlobeNewsWire
7 days ago
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing –
More Sensei Biotherapeutics Inc News

Company Profile

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Head office United States
CEO John Celebi
Employees 15
Founded 1999
Website senseibio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today